<DOC>
	<DOCNO>NCT00192673</DOCNO>
	<brief_summary>The purpose study 1. determine correct dose intramuscular administration 2. compare frequency antibody formation intramuscular administration native E.coli asparaginase PEG-asparaginase two treatment course treatment childhood lymphoblastic leukemia</brief_summary>
	<brief_title>Poly ( Ethylene Glycol ) ( PEG ) -Asparaginase During Two Treatment Courses</brief_title>
	<detailed_description>Asparaginase use treatment childhood lymphoblastic leukemia . Approximately 1/3 patient develops block antibody native E.coli asparaginase second exposure , benefit treatment thus may worse prognosis . PEG-asparaginase le immunogenic few patient may develop antibody second exposure . There publish study antibody formation treatment child PEG-asparaginase two treatment course . The first part study description pharmacokinetics PEG-asparaginase intramuscular administration order determine correct dose . The second part study comparison antibody formation two treatment course intramuscular administration og native E.coli asparaginase PEG-asparaginase . Other side effect antibody register treatment PEG-asparaginase . Finally comparison 5-year EFS group ( native E.coli asparaginase PEG-asparaginase well patient develop antibody ) evaluate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>117 year Newly diagnose ALL ( high intensive ) Treated accord NOPHO2000 protocol Treated one Nordic pediatric oncology center &lt; 1 year &gt; 18 year Newly diagnose ALL high intensive Not treat accord NOPHO2000 protocol Not treat one Nordic pediatric oncology center Allergy content Pancreatitis ( Active earlier )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Asparaginase</keyword>
	<keyword>intramuscular administration</keyword>
	<keyword>Silent antibody</keyword>
	<keyword>Childhood acute lymphoblastic leukemia</keyword>
	<keyword>Side effect</keyword>
	<keyword>5-year EFS</keyword>
</DOC>